Table 3.

The characteristics of EGFR mutant patients harboring other potentially actionable drivers treated with first-generation EGFR TKIs.

Characteristics
Total number of patients	17
Median age (range)	60 (35–72)
Gender N, (%)
Male	3 (18)
Female	14 (82)
Smoking N, (%)
Non-smoker	14 (82)
Smoker	3 (18)
Pathology N, (%)
ADC	15 (88)
Non-ADC	2 (12)
EGFR mutation type N, (%)
21L858R	12 (71)
19del	4 (23)
18G719A	1 (6)
Concomitant alterations N, (%)
MET amplification	5 (29)
ERBB2 amplification	5 (29)
ERBB2 mutations	3 (18)
MET exon 14 splicing mutation	1 (6)
RET rearrangement	1 (6)
NTRK rearrangement	1 (6)
KRAS G12C mutation	1 (6)

ADC, adenocarcinoma.